Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model

Amy Sarah Ginsburg, Ronggai Sun, Heather Calamita, Cherise P. Scott, William R. Bishai, Jacques H. Grosset
Amy Sarah Ginsburg
1Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronggai Sun
2AERAS Global TB Vaccine Foundation, Bethesda, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Calamita
3United States Patent and Trademark Office, Washington, D.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cherise P. Scott
1Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William R. Bishai
1Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques H. Grosset
1Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jgrosse4@jhmi.edu
DOI: 10.1128/AAC.49.9.3977-3979.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Fluoroquinolone resistance in tuberculosis may rapidly emerge. Mice infected with high titers of aerosolized Mycobacterium tuberculosis and treated for 8 weeks with four concentrations of moxifloxacin (0.125, 0.25, 0.50, and 1.0%) mixed into the diet had drug concentrations of 2.4, 4.1, 5.3, and 17.9 μg/ml, respectively, in blood. Selection of fluoroquinolone-resistant mutants occurred in all surviving mice.

Presently, fluoroquinolones are under study for first-line treatment of tuberculosis (9, 11). However, fluoroquinolone resistance among Mycobacterium tuberculosis strains is emerging, with important implications for treatment (1, 2, 3). To determine whether selection of fluoroquinolone-resistant mutants would occur in the murine experimental model of tuberculosis as in humans, we treated infected mice with moxifloxacin (MXF) mixed into the diet. Such a procedure permits the large differences in MXF exposure between the two species to be overcome because the half-life of MXF after oral administration is about 1.5 h in mice whereas that of MXF after oral administration in humans is 9 to 12 h (8, 9, 12). In addition, we sequenced the quinolone resistance-determining regions (QRDRs) of gyrA and gyrB in MXF-resistant isolates.

A culture of M. tuberculosis H37Rv prepared in Middlebrook 7H9-oleic acid-albumin-dextrose-catalase (OADC) was allowed to grow to the end of log phase. The MIC of MXF was determined by the agar dilution method by plating appropriate dilutions of 105 organisms/ml broth culture suspension on 7H10-OADC agar plates without and with MXF (0.06 to 8 μg/ml). The MIC of MXF was 0.25 μg/ml.

After the concentration by centrifugation of an M. tuberculosis H37Rv broth culture, 1 ml (4.35 × 108 CFU) was plated on 150 × 15 cm2 7H10-OADC agar plates without and with MXF (0.5 to 8 μg/ml). Four weeks later, an innumerable amount of CFU (>1 × 10−6) and 296 (6.8 × 10−7), 126 (2.9 × 10−7), 18 (4.1 × 10−8), and 0 (<10−8) CFU were recovered, respectively (prevalences of MXF-resistant CFU are shown in parentheses). Five single colonies were picked from 1 to 4 μg/ml MXF-containing plates, placed in 5 ml Middlebrook 7H9-OADC broth, and allowed to grow to stationary phase for sequencing of the QRDRs of gyrA and gyrB, the genes responsible for DNA gyrase-mediated fluoroquinolone resistance in M. tuberculosis. Genomic DNA was purified and amplified by PCR. Oligonucleotide primers for the QRDRs of gyrA and gyrB were used to amplify a 320-bp region of gyrA and a 375-bp region of gyrB (7, 14). The oligonucleotides for gyrA were 5′-CAGCTACATCGACTATGCGA-3′ and 5′-GGGCTTCGGTGTACCTCAT-3′, and those for gyrB were 5′-CCACCGACATCGGTGGATT-3′ and 5′-CTGCCACTTGAGTTTGTACA-3′. PCR products were purified and sequenced.

Colonies that grew on MXF-containing plates uniformly revealed single gyrA mutations, although two also exhibited single novel gyrB mutations (Table 1). For the colonies that grew at lower MXF concentrations (1 to 2 μg/ml), the missense mutation appeared in codon 94; for those that grew at 4 μg/ml, a single mutation could also be found in codon 88.

Seventy-two 6-week-old female BALB/c mice were infected by the aerosol route with an M. tuberculosis H37Rv broth culture, concentrated by centrifugation, that implanted 1.1 × 105 ± 2.1 × 104 (95% confidence interval) CFU, i.e., one log10 above the expected load. Two weeks later, prior to the initiation of treatment for 56 days, mice were moribund and the lung CFU counts of the six sacrificed mice were 5.5 × 107, 2.9 × 108, 6.9 × 108, 1.1 × 109, 3.0 × 109, and 9.6 × 109. Mice were then randomized to one of seven treatment groups, with 18 mice in the control group and 9 mice each included in groups receiving diets with the following six concentrations of MXF: 0.03%, 0.06%, 0.12%, 0.25%, 0.5%, and 1%. Due to its bitter taste, MXF was mixed with powdered sugar in a 1:10 ratio and added to the powdered food. Based on preliminary data obtained in our laboratory correlating MXF in the diet with serum levels in mice (10), it was expected that these concentrations would continuously provide MXF levels of 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 μg/ml, respectively, in serum.

Both remaining food and surviving mice were weighed every other day to monitor mean ingestion of the diet and increase in body weight. All mice had decreased diet intakes and weight loss (Table 2). All untreated control mice and mice in the lower-MXF-concentration groups (0.03 and 0.06%) died within the first 12 days of treatment, most within the first week. Only 10 mice survived after day 12 in the groups receiving MXF concentrations of 0.12% to 1.0%. Surviving mice ate 3 to 5 g diet/day. At day 56, serum from mice treated with 0.12% (one mouse), 0.25% (four mice), 0.5% (three mice), and 1.0% (two mice) MXF in the diet had concentrations of 2.4, 4.1, 5.3, and 17.9 μg/ml, respectively, in serum. These were higher than expected by approximately double. The lungs of the single surviving mouse in the 0.12% concentration group had 6.7 × 104 CFU. The lung CFU counts of the four mice treated with a 0.25% concentration were 4.8 × 103, 6.9 × 103, 4.3 × 104, and 5.0 × 104 (mean, 2.6 × 104). The CFU counts in the lungs of the three mice in the 0.5% concentration group were 2.5 × 102, 5.0 × 102, and 1.9 × 103 (mean, 8.8 × 102), and those in the two mice in the 1% concentration group were 1.0 × 102 and 2.0 × 102 (mean, 1.5 × 102). These data suggest an increased reduction of the CFU/lung values in relation to the increase of MXF concentration in the diet (Table 3).

Up to five single colonies were picked from each MXF-containing plate, placed in 5 ml Middlebrook 7H9-OADC broth, and allowed to grow to stationary phase for PCR amplification and sequencing of the QRDRs of gyrA and gyrB. All of the tested isolates from mice fed on MXF-containing diets yielded MXF-resistant mutants with mutations in QRDRs of gyrA. Sequencing revealed single mutations in codons 90, 91, and 94 of gyrA (Table 4). No double mutations were detected.

Although the collective mouse and food weights were monitored closely throughout the experiment, there was only a one-time collective measurement of MXF in the serum per group taken on completion of the experiment. Thus, we have no direct measurement of the serum levels of MXF achieved during the entire course of the experiment. While mice eventually manifested very high MXF concentrations in blood, poor diet consumption early in the course of therapy likely resulted in lower MXF concentrations at the crucial therapeutic stage when the organism load and the risk of selecting resistant mutants were highest. Therefore, the present experiment indirectly demonstrates the importance of achieving the maximal antibacterial effect early in the course of therapy to reduce the risk of resistance. Finally, one might consider that the poor diet consumption of the mice was analogous to poor adherence in humans, so that the present study also inadvertently demonstrates the adverse impact of nonadherence on the promotion of fluoroquinolone resistance. This is cause for concern in the current context of increasing numbers of fluoroquinolone prescriptions worldwide (1, 3, 4, 5, 6, 13).

View this table:
  • View inline
  • View popup
TABLE 1.

gyrA and gyrB QRDR mutations of in vitro isolates of M. tuberculosis H37Rv grown on plates containing MXF (1, 2, and 4 μg/ml)

View this table:
  • View inline
  • View popup
TABLE 2.

Mouse weights before and after initiation of MXF mixed into the diet

View this table:
  • View inline
  • View popup
TABLE 3.

Number and percentage of colonies isolated on control and MXF-containing plates after 8 weeks' treatment

View this table:
  • View inline
  • View popup
TABLE 4.

Determination of mutation in QRDRs of gyrA and gyrB of MXF-resistant colonies grown from day 56 lung homogenates

ACKNOWLEDGMENTS

We are indebted to Charles Peloquin for determining the serum concentrations of MXF in blood and to Eric Nuermberger and Ian Rosenthal for helpful reviews of the manuscript.

We gratefully acknowledge the support of the Global Alliance for Tuberculosis Drug Development, National Institutes of Health grant AI43846, National Institute of Allergy and Infectious Diseases grant R01 43846, a supplement to National Institute of Allergy and Infectious Diseases grant R01 36973, and fellowship support to R.S. from the Potts Foundation and the American Lung Association.

FOOTNOTES

    • Received 3 June 2005.
    • Returned for modification 4 June 2005.
    • Accepted 9 June 2005.
  • Copyright © 2005 American Society for Microbiology

REFERENCES

  1. 1.↵
    Bozeman, L., W. Burman, B. Metchock, M. Weiner, and F. Gordin. 2002. Fluoroquinolone susceptibility among selected Mycobacterium tuberculosis isolates from the United States and Canada. Am. J. Respir. Crit. Care Med.165(Suppl.):A18.
    OpenUrl
  2. 2.↵
    Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis.3:432-442.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Ginsburg, A. S., N. Hooper, N. Parrish, K. E. Dooley, S. E. Dorman, J. Booth, M. Diener-West, W. G. Merz, W. R. Bishai, and T. R. Sterling. 2003. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis.37:1448-1452.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Ginsburg, A. S., S. C. Woolwine, N. Hooper, W. H. Benjamin, Jr., W. R. Bishai, S. E. Dorman, and T. R. Sterling. 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med.349:1977-1978.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Hong Kong Chest Service/British Medical Research Council. 1992. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber. Lung Dis.73:59-67.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Iseman, M. D. 1993. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med.329:784-791.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Kocagoz, T., C. J. Hackbarth, I. Unsal, E. Y. Rosenberg, H. Nikaido, and H. F. Chambers. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother.40:1768-1774.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Miyazaki, E., M. Miyazaki, J. M. Chien, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother.43:85-89.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Nuermberger, E., T. Yoshimatsu, S. Tyagi, W. R. Bishai, and J. H. Grosset. 2003. Activity of moxifloxacin at clinically relevant dosages in the mouse model of tuberculosis. Am. J. Respir. Crit. Care Med.167(Suppl.):A433.
    OpenUrlCrossRef
  10. 10.↵
    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med.169:421-426.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    O'Brien, R. J. 2003. Development of fluoroquinolones as first-line drugs for tuberculosis—at long last! Am. J. Respir. Crit. Care Med.168:1266-1268.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Stass, H., A. Dalhoff, D. Kubitza, and U. Schuhly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother.42:2060-2065.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Sullivan, E. A., B. N. Kreiswirth, L. Palumbo, V. Kapur, J. M. Musser, A. Ebrahimzadeh, and T. R. Frieden. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet345:1148-1150.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother.38:773-780.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model
Amy Sarah Ginsburg, Ronggai Sun, Heather Calamita, Cherise P. Scott, William R. Bishai, Jacques H. Grosset
Antimicrobial Agents and Chemotherapy Aug 2005, 49 (9) 3977-3979; DOI: 10.1128/AAC.49.9.3977-3979.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model
Amy Sarah Ginsburg, Ronggai Sun, Heather Calamita, Cherise P. Scott, William R. Bishai, Jacques H. Grosset
Antimicrobial Agents and Chemotherapy Aug 2005, 49 (9) 3977-3979; DOI: 10.1128/AAC.49.9.3977-3979.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Aza Compounds
fluoroquinolones
Mycobacterium tuberculosis
quinolines
tuberculosis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596